Securities code: 301166 securities abbreviation: youningwei Announcement No.: 2022-009 Shanghai youningwei Biological Technology Co., Ltd
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Basic information of raised funds
The registration was approved by the reply on Approving the registration of the initial public offering of shares of Shanghai Youning weishengwu Technology Co., Ltd. (zjxk [2021] No. 3556) issued by the China Securities Regulatory Commission and approved by the Shenzhen Stock Exchange, Shanghai Youning Weisheng Technology Co., Ltd. (hereinafter referred to as “the company”) issued 21666668 ordinary shares (A shares) in RMB for the first time, with a par value of RMB 1.00 per share and an issue price of RMB 86.06 per share. The total amount of funds raised was RMB 1864633400. After deducting the issuance cost of RMB 269116200 (excluding tax), The net amount of funds actually raised was 1595.5173 million yuan.
All the above-mentioned raised funds have been received, and Tianzhi International Certified Public Accountants (special general partnership) has verified the availability of the above-mentioned funds and issued the capital verification report (tzyz [2021] No. 45819). After the above-mentioned raised funds are received, the company manages the deposit and use of the raised funds in a special account, and has signed the tripartite supervision agreement on raised funds with the special account bank and the sponsor.
2、 Use of raised funds
The basic information of the investment projects of the funds raised from the public offering of shares disclosed in the prospectus of the company’s initial public offering and listing on the gem is as follows: unit (10000 yuan)
S / n project name estimated project investment estimated use of raised funds
1. Online marketing network and information construction project 8079.60 8079.60
2 offline marketing and service network upgrading project 6828.15 6828.15
3. R & D center construction project 8431.58 8431.58
4. Supplementary working capital project 5000.00 5000.00
Total 28339.33
The net amount of funds actually raised by the company is 1595517300 yuan, of which the amount of over raised funds is 131212400 yuan.
3、 Relevant information about the construction projects invested with some over raised funds this time
(I) basic information of construction projects invested with some over raised funds
1. Project overview
On May 7, 2020, the second extraordinary general meeting of the company in 2020 deliberated and approved the proposal on investment in Nanjing biological park and the proposal on consideration of project investment and construction agreement and supplementary agreement. The company plans to build an independent brand product production base project in Nanjing, Jiangsu Province, with a total investment of about 280 million yuan.
2. Project Name: independent brand product production base project (biological agent production line construction project) 3. Project location: the intersection of Qinyin Avenue and Runli Road, yongyang Industrial Park, Lishui District, Nanjing
According to the agreement on investment and construction of industrial projects in Lishui district signed by the company and Jiangsu Xingzhuang construction and Development Group Co., Ltd. on May 17, 2020, the company plans to invest in the construction of “Nanjing Biological Park” project in Lishui yongyang Industrial Park, with a new plant of 26000 m2 and a project land of about 25.89 mu. In August 2020, the land supply meeting for industrial projects to be listed in Lishui District considered and approved the construction project.
On July 25, 2021, the company signed the tripartite agreement on the change of contract subject with Jiangsu yongyang construction and Development Group Co., Ltd. (formerly known as “Jiangsu Xingzhuang construction and Development Group Co., Ltd.”) and yongyang sub district office of Lishui District People’s Government of Nanjing, and the relevant rights of Jiangsu yongyang construction and Development Group Co., Ltd. under the Lishui District industrial project investment and construction agreement The obligations shall be enjoyed and undertaken by yongyang sub district office of Lishui District People’s Government of Nanjing. The supplementary agreement was signed with yongyang sub district office of Lishui District People’s Government of Nanjing on July 30, 2021.
Among them, on April 26, 2021, the company and Lishui branch of Nanjing Planning and natural resources bureau signed the contract for the transfer of the right to use state-owned construction land (Contract No.: 3201242021cr0022). On June 7, 2021, the company has obtained the real property right certificate of the plot (property right certificate No.: Su (2021) Ningli real property right No. 0012225). In addition, the project has obtained the investment project filing certificate of Jiangsu Province (filing No.: Li Ping tou Bei [2020] No. 615) and the construction project planning license (Certificate No.: Jian Zi No. 320117202100249)
4. Project implementation subject: Nanjing Youning Weisheng Technology Co., Ltd. (hereinafter referred to as “Nanjing youningwei”) unified social credit Code: 91320117ma1yp7qf36
Legal representative: Leng Zhaowu
Address: No. 688, Tianshengqiao Avenue, yongyang street, Lishui District, Nanjing
Enterprise type: limited liability company (sole proprietorship of legal person invested or controlled by non natural person)
Registered capital: 20 million yuan
Date of establishment: July 11, 2019
Business term: from July 11, 2019 to no fixed term
Business scope: R & D, production and sales of reagents, consumables and equipment in the fields of biotechnology, medical diagnosis, biological products and medical science and technology; Technical consultation, technology transfer and technical services in the fields of biotechnology, medical diagnosis, biological products and medical science and technology; Sales of chemical products and raw materials (excluding hazardous chemicals); Software development and sales; Property management services and house leasing; Self support and agency of import and export business of various commodities and technologies, except those limited or prohibited by the state. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)
5. Investment scale and capital source: the planned investment of the project is 280.4852 million yuan. It is proposed to use the over raised capital of 280.4852 million yuan.
The company will provide the above raised funds to the project by gradually increasing the capital of Nanjing youningwei according to the construction progress of the project.
6. Specific construction contents
The project plans to invest 280.4852 million yuan, including 4.5 million yuan of land cost, 153.0913 million yuan of civil engineering, 84.5995 million yuan of software and hardware investment, 26.7 million yuan of research and development cost and 11.5944 million yuan of initial working capital, to carry out the construction of independent brand product production base project.
7. Project construction period: 4 years
8. Composition of project investment estimation
The total investment of the project is 280.4852 million yuan. The specific composition of the project investment is as follows:
No. proportion of project investment amount (10000 yuan)
1. Land cost 450.00 1.60%
2 Civil Engineering 15309.13 54.58%
2.1 plant 1 2597.51 9.26%
2.2 plant 2 4532.37 16.16%
2.3 plant 3 5621.62 20.04%
2.4 consumables warehouse 333.23 1.19%
2.5 other construction costs 1570.17 5.60%
2.6 reserve fund 654.24 2.33%
3 software and hardware investment 8459.95 30.16%
Research and development fee 269.00%
5. Initial working capital 1159.44 4.13%
Total 28048.52 100.00%
9. Necessity analysis of project construction
(1) It meets the innovative development needs of China’s life science industry
Biological industry is the most active and far-reaching emerging industry in the 21st century. It is the main direction of China’s strategic emerging industry. It is of great significance for China to seize the commanding heights of a new round of scientific and technological revolution and industrial revolution, accelerate the growth Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) , develop a new economy, cultivate new driving forces, and build a “healthy China”.
The implementation of this project is to highlight technological innovation, establish a technological innovation system, strengthen the research and development of products with independent intellectual property rights, promote industrial technological progress, actively develop products with high technical content and meet personalized needs, and produce high value-added scientific research reagent products that reach the international leading level. It is to gradually expand a broader downstream market, A necessary way to enhance the competitiveness of products outside China.
(2) It helps to improve the company’s independent innovation and R & D ability and enhance the company’s sustainable competitiveness
With the gradual popularization of the use of immune test related products around the world, increasing R & D investment, enriching product structure and improving the independent innovation ability of enterprises have become the key factors to ensure the stable development of the company. The company has been committed to the research and development of immune experiment related products. With the rapid development of downstream application fields, the research and development of scientific research projects are difficult, the technical requirements are high, the experimental cycle increases and the project management is more complex. At the same time, with the continuous expansion of the application fields of detection kits and fluorescent antibody products, the quality of personnel, equipment conditions The experimental environment and hardware management put forward higher requirements. At present, the company’s own brand has many R & D projects under way, and the existing R & D conditions are difficult to undertake more R & D tasks, which restricts the improvement of the company’s technical strength to a certain extent.
In this project, the company will purchase advanced biological instruments and equipment, improve the company’s R & D environmental conditions, introduce high-end R & D talents and optimize the structure of R & D personnel, so as to improve the existing R & D status and meet the needs of the future market development of the industry. The implementation of the project is conducive to improving the company’s independent innovation and R & D ability, enriching the product line, and providing technical guarantee for the innovation of the company’s products and the growth of performance.
(3) The inevitable way to realize the company’s development strategy
With the deepening of human research in the field of life science, scientific research reagents, instruments and equipment and other related products, as the core tools of scientific research, are facing high demand prospects. Developed countries such as Europe, America and Japan started their research in the field of Bioscience earlier, attached importance to R & D investment, and were in a leading position in terms of scale, market and technical level. Driven by economic globalization, China’s biological reagent sales industry has developed rapidly, but the market concentration is low, the product homogenization is serious, and an enterprise with international influence has not been formed. The company is committed to building a leading one-stop service provider in the field of life sciences in China and becoming an enterprise with international influence; At the same time, we will fully develop the R & D and mass production of our own brands and related products. The implementation of this strategy requires efforts to improve the company’s comprehensive strength, including R & D capacity, production capacity, agency capacity, channel development and control capacity, sales capacity, customer service capacity, etc., provide support for the company’s independent R & D and production products and brands, and increase investment in sales network construction and brand image promotion.
The company adheres to the development principle of taking its own brand immune experiment related products and technical services as its main business, continuously understands the changes of market demand, increases relevant investment in R & D and production, and improves the market response speed. Through the construction of this project, the company has invested R & D efforts in the fields of diagnostic reagents, high-sensitivity detection reagents, highly purified antibody proteins, detection equipment equipped with high-end detection platform, high-channel detection instruments, and more detection service technologies. At the same time, the large-scale production of reagent detection kits and fluorescent antibodies is a key step to realize the company’s development strategy, It is also an important measure to promote the localization of relevant products in China. Based on the existing technology, the company will accelerate the R & D and transformation of new products and materials, promote the pace of marketization, and provide high-level experimental technical services while strictly controlling the product quality.
10. Feasibility analysis
(1) China’s biological reagent market has huge space
Biological reagent industry is an emerging industry developed in China in recent years. Compared with European and American countries, it started late and lagged behind in industrial development. Compared with foreign biological reagents, China’s biological reagents
